Total tissue factor pathway inhibitor and venous thrombosis
- 1 January 2010
- journal article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 104 (08) , 207-212
Abstract
Summary: Tissue factor pathway inhibitor (TFPI) inhibits tissue factor, a potent coagulation initiator. Limited evidence suggests that low TFPI levels are associated with increased risk of venous thromboembolism (VTE). We measured total TFPI in a nested case-control study in the Longitudinal Investigation of Thromboembolism Etiology. Control subjects were frequency matched 2:1 to cases on age, sex, race, and cohort. Odds ratios (ORs) for VTE by TFPI levels were computed using logistic regression models adjusting for age, race, sex, coagulation factors (factors VII, VIII, IX, XI, D-dimer), and body mass index (BMI). To evaluate for greater than additive interactions, we calculated the percent relative excess risk due to interaction between TFPI and other VTE risk factors. A total of 534 cases of VTE occurred and matched to 1,091 controls. Mean baseline TFPI in ng/ml (standard deviation) in those who developed VTE and controls was 36.4 (12.8) and 35.0 (11.1), respectively. Higher TFPI was associated with male sex, age, BMI, factors VII, VIII, IX, XI, and D-dimer. TFPI level did not differ by ethnicity, factor V Leiden, or pro-thrombin G20210A. Compared with those in the upper 95%, the bottom 5% of TFPI had an age-, sex-, race-, and study-adjusted OR (95% CI) of 1.35 (0.86, 2.12) for VTE. Adjusting for factors VII, VIII, IX, and XI the OR was 1.93 (1.05, 3.53). Further addition of D-dimer and BMI to this model decreased the OR to 1.70 (0.98, 2.93). Low TFPI did not demonstrate greater than additive interaction with other VTE risk factors.Keywords
Funding Information
- ARIC (N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC 55019, N01-HC-55020, N01-HC-55021, N01-HC-55022)
- National Heart, Lung, and Blood Institute, Bethesda, MD. CHS (N01-HC-85079 through N01-HC-85086, N01-HC-35129 and N01-HC-15103)
- National Heart, Lung, and Blood Institute ((R01 HL59367))
This publication has 22 references indexed in Scilit:
- Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiologyThe American Journal of Medicine, 2004
- Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and strokeThrombosis and Haemostasis, 2004
- Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosisBlood, 2003
- Fibrin fragment D-dimer and the risk of future venous thrombosisBlood, 2003
- Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE)The American Journal of Medicine, 2002
- D-Dimer as a Risk Factor for Deep Vein Thrombosis: The Leiden Thrombophilia StudyThrombosis and Haemostasis, 2002
- Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosisBritish Journal of Haematology, 2001
- The Effects of Hormone Replacement Therapy (HRT) on Hemostatic Variables in Women with Previous Venous Thromboembolism – Results from a Randomized, Double-Blind, Clinical TrialThrombosis and Haemostasis, 2001
- The cardiovascular health study: Design and rationaleAnnals of Epidemiology, 1991
- The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.1989